Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals has reported Other Non-Current Assets for 6 years, with the latest figure at $2.5 million in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 72.29% year-over-year to $2.5 million in Q2 2026; TTM through Jun 2026 was $2.5 million, a 72.29% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 72.75% from the prior year.
• Other Non-Current Assets was $2.5 million for Q2 2026 at Amylyx Pharmaceuticals, roughly flat from $2.5 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.5 million in Q3 2025, with the low at $456000.0 in Q1 2022.
• Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $719000.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets sank 79.1% in 2022, then surged 101.81% in 2025.
• Over 5 years, Other Non-Current Assets stood at $719000.0 in 2022, then changed by 0.0% to $719000.0 in 2023, then surged by 101.11% to $1.4 million in 2024, then soared by 72.75% to $2.5 million in 2025, then gained by 0.08% to $2.5 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.5 million (Q2 2026), $2.5 million (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.